Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 12/20 | 0.48 |
| ▸ | INSR | P06213 | 5/20 | 0.48 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19175225 | 0.88 | DRD2 (0.44) | ALKINSRMAP3K12DRD2 | |
| SCHEMBL12705391 | 0.88 | ALK (0.39) | ALKINSR | |
| SCHEMBL12705526 | 0.87 | ALK (0.47) | ALKINSRKCNH2DRD2TRPC6 | |
| SCHEMBL12705369 | 0.85 | ALK (0.45) | ALKINSRKCNH2TRPC6 | |
| SCHEMBL17304109 | 0.85 | MAP3K12 (0.38) | ALKINSRMAP3K12TLR9TLR8 | |
| SCHEMBL20567095 | 0.85 | ALK (0.39) | ALKINSRKCNH2TRPC6 | |
| SCHEMBL1014752 | 0.84 | ALK (0.43) | ALKINSRKCNH2TRPC6 | |
| SCHEMBL12705410 | 0.83 | ALK (0.48) | ALKINSRTLR9TLR8TLR7 | |
| SCHEMBL12705469 | 0.83 | ALK (0.49) | ALKINSRKCNH2DRD2TRPC6 | |
| SCHEMBL17304235 | 0.81 | ALK (0.34) | ALKINSRKCNH2TRPC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271630-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-03-23 | — | — | EP | disclosed |
| EP-2271630-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-03-23 | — | — | EP | disclosed |
| CN-102131788-B | Compounds and compositions as protein kinase inhibitors | IRM LLC | 2014-03-19 | — | — | CN | disclosed |
| US-8592432-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-11-26 | — | — | US | disclosed |
| EP-2537830-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-12-26 | — | — | EP | disclosed |
| CN-102131788-A | Compounds and compositions as protein kinase inhibitors | IRM LLC | 2011-07-20 | — | — | CN | disclosed |
| US-20110135668-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-06-09 | — | — | US | disclosed |
| US-20110135668-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-06-09 | — | — | US | disclosed |
| US-20110135668-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-06-09 | — | — | US | disclosed |
| EP-2311807-A1 | Compounds and composition as protein kinase inhibitors | IRM LLC (BM) | 2011-04-20 | — | — | EP | disclosed |
| EP-2271630-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009126515-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126515-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-10-15 | — | — | WO | disclosed |
| WO-2008073687-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135668-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ROS1, INSR, IGF1R | ALK 6/4885INSR 2/4885MAP3K12 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.